Compare Mesoblast Limited (MESO) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Suncor Energy Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Suncor Energy Inc. trades at $63.12 (market cap $72.86B). The key difference: Suncor Energy Inc. is far larger — about 33.6× Mesoblast Limited's market cap, and Suncor Energy Inc. pays a 2.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SU | |
|---|---|---|
Market Cap | $2.17B | $72.86B |
Sector | Technology | Energy |
52-Week High | $20.96 | $69.73 |
52-Week Low | $12.88 | $38.17 |
Enterprise Value | $2.17B | $80.99B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Suncor Energy (SU) trades at $62.62, up 0.3% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with a P/E of 16.85, net income margin of 11.62%, and consistent earnings beats in recent quarters. Recent news highlights operational improvements and record production driving the stock's 49% annual gain. Cash flow remains positive with $166M net cash flow in 2025, supported by disciplined capital allocation.
SU presents a compelling investment case with attractive valuation metrics and strong institutional support, though exposure to oil price volatility and recent RSI overbought signals warrant caution. The company's integrated operations and shareholder returns provide stability, but investors should monitor commodity price trends and Q2 earnings results against the $2.14 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
